NCT00209898终止4 期
Hepatitis C Treatment of Inmates. A Randomized, Open-label Study Evaluating the Feasibility, Safety and Efficacy of Treatment With Peginterferon Alfa-2a in Combination With Ribavirin in Inmate Patients With Chronic Hepatitis C
Haukeland University Hospital2 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2003年8月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 42
- 试验地点
- 2
- 主要终点
- - Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (>50 IU/mL).
研究概览
简要总结
Hepatitis C infection is a prevalent chronic disease. It is particularly prevalent among intravenous drug abusers. Bergen fengsel is a regional prison housing 250 inmates, of which as many as 70 are recorded HCV RNA PCR positive annuallly. In this study inmate males and females will be randomized to standard screening and initiation procedure, or to a rapid initiation procedure in the hospital's infectious diseases outpatient clinic. The study aims at studying if rapid inclusion will increase the possibility to conclude treatment while the prisoner still is incarcerated, thus improve the chances of reaching a sustained virologic response, compared to standard inclusion, where prisoners, as other out patients will wait for inclusion for several months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Serologic evidence of chronic hepatitis C infection by an anti-HCV test
- •Serum HCV-RNA quantifiable at > 600 IU/mL or 1000 copies/mL by the Roche AMPLICOR HCV MONITOR Test, v2.0
- •Patients with both normal or elevated serum ALT are eligible
- •Compensated liver disease (Child-Pugh grade A clinical classification)
- •Patients with cirrhosis or transition to cirrhosis must have an abdominal ultrasonography, CT scan or MRI scan without evidence of hepatocellular carcinoma and a serum AFP < 100 ng/mL within 2 months of randomization
- •Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24 hour period prior to first dose of study drug
- •All fertile males and females receiving RBV must be using two forms of effective contraception during treatment and during the 6 months after treatment ends
排除标准
- •Women with ongoing pregnancy or breat feeding
- •Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic soses of steroids and radiation) < 6 months prior to the first dose of study drug
- •Any investigational drug < 6 weeks prior to the first dose of study drug Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBsAg, anti-HBc Ab, anti-HIV Ab.
- •History or evidence of a medical condition associated with chronic liver disease other than HCV (e.g. hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
- •History or evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- •Neutrophil count < 1500/mm or platelet count < 90,000 cells/mm at screening
- •Serum creatinine level > 1,5 times the ULN at screening
- •History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or neuroleptica at therapeutic doses for major depression or psychosis, respectively for at least 3 months at any previous time, or any history of the following; a suicidal attempt, hospitalization for psychiatric disease or a period of disability due to psychiatric disease
- •History of severe seizure disorder or current anticonvulsant disease
- •History of immunologically mediated disease (e.g. IBD, ITP, LED, AIHA, scleroderma, severe psoriasis or RA etc.)
- •History or other evidence of chronic pulmonary disease associated with functional limitation
- •History of major organ transplantation with an existing functional graft
- •History of severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial infarction within 6 months of ventricular arrhythmias requiring ongoing treatment, unstable angina or other significant CVD)
- •History or other evidence of severe illness, malignancy or other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- •Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)
- •Evidence of ongoing drug abuse (including excessive alcohol consumption)
- •Inability or unwillingness to provide informed consent or abide by the requirements of the study
- •Male partners of women who are pregnant
- •Hemoglobin < 12 g/dL in women or < 13g/dL in men at screening
- •Any patient with an increased baseline risk for anemia or for whom anemia would be medically problematic
- •Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgement of the investigator, an acuter decrease in hemoglobin by up to 4 g/dL would not be well-tolerated
研究组 & 干预措施
Rapid standard of care
Active Comparator
Rapid standard of care treatment after screening
干预措施: Fast initiation procedure (Procedure)
Ordinary standard of care
Active Comparator
Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
干预措施: Fast initiation procedure (Procedure)
结局指标
主要结局
- Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (>50 IU/mL).
- adherence
次要结局
- - Other laboratory tests
- - adverse event rate and profile
- - Medical Outcomes Study 36 Item Short Form health Survey (SF-36)
- Percentage of patients with non-detectable HCV-RNA at study week 12, 24 and 48 as measured by Roche AMPLICOR HCV Test v2.0 (<50 IU/mL).
- - Hemoglobin
研究者
Steinar Skrede
Consultant
Haukeland University Hospital
研究点 (2)
Loading locations...
相似试验
撤回
不适用
Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)Chronic HIV InfectionNCT05649202Assistance Publique - Hôpitaux de Paris24
已完成
不适用
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)Hepatitis C, ChronicNCT00725751Merck Sharp & Dohme LLC353
已完成
不适用
Direct Acting Antivirals for HCV Infection in Kidney Transplant RecipientsHepatitis C, ChronicKidney Transplant ComplicationsNCT03880682Istanbul University30
撤回
4 期
Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)HCV InfectionNCT04235049University of Maryland, Baltimore
已完成
不适用
Screening for Chronic Hepatitis C Virus in Hospitalized PatientsHepatitis CNCT04437277Hospital St. Joseph, Marseille, France5,000